Healthcare technology company Medtronic plc (NYSE:MDT) announced on Wednesday that it has secured US Food and Drug Administration (FDA) approval for its Simplera continuous glucose monitor (CGM), a compact device designed for ease of use.

Simplera CGM offers a discreet and user-friendly design, expanding Medtronic's CGM portfolio. The device is already available in Europe and will be launched in the United States following FDA clearance for the accompanying smart insulin pen app.

Medtronic also announced a global partnership with medical devices and healthcare solutions company Abbott (NYSE:ABT) to develop an integrated CGM solution compatible with Medtronic's insulin delivery devices.

The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.